Clinical Trials Directory

Trials / Conditions / Fibrillation, Atrial

Fibrillation, Atrial

12 registered clinical trials studyying Fibrillation, Atrial — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingAtrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women
NCT06200311
University Medical Center GroningenN/A
RecruitingMedical and Sociological Characterization of the Population of Patients Admitted for a First Ablation of Atria
NCT06618833
University Hospital, ToulouseN/A
Enrolling By InvitationThromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (T
NCT06874894
Chung-Ang University Hosptial, Chung-Ang University College of Medicine—
WithdrawnArtificial Intelligence Use for the Detection of Atrial Fibrillation Drivers
NCT03401931
Hospital St. Joseph, Marseille, France—
CompletedDetecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (From the DAF-ESUS Reg
NCT04761315
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz—
CompletedAtrial Fibrillation and Non-obstructive Coronary Lesions
NCT04537507
Medical University of Bialystok—
CompletedEvaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart
NCT00911300
GlaxoSmithKlinePhase 2
CompletedEvaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibri
NCT00402363
GlaxoSmithKlinePhase 3
TerminatedOdiparcil QT Definitive Study
NCT00437242
GlaxoSmithKlinePhase 1
CompletedUse Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For
NCT00240643
GlaxoSmithKlinePhase 2
CompletedOdiparcil For The Prevention Of Venous Thromboembolism
NCT00244725
GlaxoSmithKlinePhase 2
CompletedPrevention Of Recurrence Of Atrial Fibrillation
NCT00041496
GlaxoSmithKlinePhase 2